Literature DB >> 19307257

Perceptions of disease and health-related quality of life among patients with gout.

Susan J Lee1, Jan D Hirsch, Robert Terkeltaub, Dinesh Khanna, Jasvinder A Singh, Andrew Sarkin, Arthur Kavanaugh.   

Abstract

OBJECTIVE: To assess the impact of gout on health-related quality of life (HRQoL) among patients in three large US cities.
METHODS: Gout patients completed the Short Form-36 (SF-36) and a series of questions regarding their gout, comorbidities and demographics. Their physicians confirmed the gout diagnosis and evaluated the severity of patient's gout. The differences in mean norm-based SF-36 scores between the US norms and gout patients and between subgroups of gout patients were calculated. The relative weight and significance of gout-related characteristics associated with patients' HRQoL were also calculated.
RESULTS: The majority of the patients were males with a mean age of 62.2 years and median disease duration of 13.8 years. Most were overweight/obese with several comorbidities. Half of the patients experienced three or more gout attacks per year with a typical gout attack involving five joints and lasting for at least 4 days. The Physical Component Summary (PCS) and Mental Component Summary (MCS) was significantly lower for gout patients (P < 0.002 and P < 0.001, respectively). Among gout patients, the mean PCS and MCS were lower for those with more frequent gout attacks and greater number of affected joints (P < 0.005 and P < 0.001, respectively). After adjusting for age, gender and comorbidities, the number of joints involved during a typical and the worst gout attack had the greatest impact on patient's PCS and MCS.
CONCLUSION: Gout patients had clinically significant lower HRQoL than their age-matched US norm. Comorbidities and several additional gout-related factors significantly impacted the overall HRQoL.

Entities:  

Mesh:

Year:  2009        PMID: 19307257      PMCID: PMC2722803          DOI: 10.1093/rheumatology/kep047

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

Review 1.  Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Authors:  Geoffrey R Norman; Jeff A Sloan; Kathleen W Wyrwich
Journal:  Med Care       Date:  2003-05       Impact factor: 2.983

Review 2.  Clinical practice. Gout.

Authors:  Robert A Terkeltaub
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

3.  The prevalence of major depression or dysthymia among aged Medicare Fee-for-Service beneficiaries.

Authors:  Nancy T McCall; Peggy Parks; Kevin Smith; Greg Pope; Michelle Griggs
Journal:  Int J Geriatr Psychiatry       Date:  2002-06       Impact factor: 3.485

4.  Gout, diet, and the insulin resistance syndrome.

Authors:  Adel G Fam
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

Review 5.  Gout: on the brink of novel therapeutic options for an ancient disease.

Authors:  Jeffry D Bieber; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2004-08

6.  Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.

Authors:  J E Ware; M Kosinski; M S Bayliss; C A McHorney; W H Rogers; A Raczek
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

Review 7.  Gout and hyperuricemia.

Authors:  R Roubenoff
Journal:  Rheum Dis Clin North Am       Date:  1990-08       Impact factor: 2.670

8.  Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II.

Authors:  Katarzyna Piotrowicz; Katia Noyes; Jeffrey M Lyness; Scott McNitt; Mark L Andrews; Andrew Dick; W Jackson Hall; Arthur J Moss; Wojciech Zareba
Journal:  Eur Heart J       Date:  2007-02-12       Impact factor: 29.983

Review 9.  A literature review of the epidemiology and treatment of acute gout.

Authors:  Karissa Y Kim; H Ralph Schumacher; Elke Hunsche; Albert I Wertheimer; Sheldon X Kong
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

10.  Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study.

Authors:  H S J Picavet; N Hoeymans
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more
  38 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  Identification of Gout Flares in Chief Complaint Text Using Natural Language Processing.

Authors:  John D Osborne; James S Booth; Tobias O'Leary; Amy Mudano; Giovanna Rosas; Phillip J Foster; Kenneth G Saag; Maria I Danila
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

Review 3.  Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.

Authors:  Allison Guttmann; Svetlana Krasnokutsky; Michael H Pillinger; Adey Berhanu
Journal:  Ther Adv Drug Saf       Date:  2017-09-13

4.  Minimally important differences of the gout impact scale in a randomized controlled trial.

Authors:  Dinesh Khanna; Andrew J Sarkin; Puja P Khanna; Marian M Shieh; Arthur F Kavanaugh; Robert A Terkeltaub; Susan J Lee; Jasvinder A Singh; Jan D Hirsch
Journal:  Rheumatology (Oxford)       Date:  2011-03-03       Impact factor: 7.580

Review 5.  A Systematic Review of the Economic and Humanistic Burden of Gout.

Authors:  Gemma E Shields; Stephen M Beard
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

6.  Experiences of gout-related disability from the patients' perspective: a mixed methods study.

Authors:  Peter M ten Klooster; Harald E Vonkeman; Martijn A H Oude Voshaar; Christina Bode; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-08       Impact factor: 2.980

7.  Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.

Authors:  Puja P Khanna; Fernando Perez-Ruiz; Paul Maranian; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2010-12-08       Impact factor: 7.580

8.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

9.  Cost-effectiveness of febuxostat in chronic gout.

Authors:  Stephen M Beard; Birgitta G von Scheele; George Nuki; Isobel V Pearson
Journal:  Eur J Health Econ       Date:  2013-05-30

10.  Performance of Gout Impact Scale in a longitudinal observational study of patients with gout.

Authors:  Beth Wallace; Dinesh Khanna; Cleopatra Aquino-Beaton; Jasvinder A Singh; Erin Duffy; David Elashoff; Puja P Khanna
Journal:  Rheumatology (Oxford)       Date:  2016-02-16       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.